Allogeneic iNKT cell therapy to improve HSCT outcomes
Official title: Developing allogeneic iNKT cell adoptive therapy to improve outcomes for HSCT indications
Funded at Mink Therapeutics INC · NIH-11333020 · Data updated 2026-11-12
A new off-the-shelf immune cell therapy using donor iNKT cells aims to reduce complications and improve immune reconstitution after stem cell transplantation.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mink Therapeutics INC NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | May 9, 2025 |
| Project end | April 30, 2027 |
| Funding year | 2026 |
| Award (this year) | $306,500 |
| NIH project number | 5R41AI192061-02 |
| Project ID | NIH-11333020 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults undergoing hematopoietic stem cell transplantation who are at risk for graft-versus-host disease or poor engraftment.
✕Less likely to help
This early-stage work does not yet involve direct patient treatment and may not benefit individuals without HSCT indications.
What this research studies
This project tests agenT-797, an off-the-shelf iNKT cell product, in the context of hematopoietic stem cell transplantation to lower graft-versus-host disease and support better engraftment. The work combines preclinical studies with translational aims to understand how agenT-797 modulates the patient’s immune system after transplant. No patient treatment results are reported yet, but the goal is to build a safer, more effective HSCT process that could be tested in future clinical trials.
Why it matters
Potential benefit: If successful, this therapy could make HSCT safer and more effective by reducing immune-related complications and improving immune recovery.
How similar studies have gone: Prior early-phase trials of agenT-797 in other contexts showed safety and immunomodulatory activity, supporting further development.
Where this research is happening
-
Mink Therapeutics INC
New York, United States Active
Researchers
- Principal investigator: Le Tonqueze, Olivier — Mink Therapeutics INC
- Study coordinator: Le Tonqueze, Olivier
Related research
Other NIH-funded projects on the same topics.
-
Improving outcomes for stem cell transplants using specialized immune cells
This study is testing a new treatment called agenT-797 that uses special immune cells to help make stem cell transplants safer and more effective for patients, without the need for matching or extra preparation.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.